Cardiovascular disease and serum defensin levels in systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 30, Issue 3, 2012, Pages 364-370

  Vordenbäumen, Stefan ^a   Sander, Oliver ^a   Bleck, Ellen ^a   Schneider, Matthias ^a   Fischer Betz, Rebecca ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antimicrobial peptide; Cardiovascular disease; Defensin; Systemic lupus erythematosus

Indexed keywords

BETA DEFENSIN 2; DEFENSIN; HUMAN NEUTROPHIL PEPTIDE; UNCLASSIFIED DRUG;

AGE; ANGINA PECTORIS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CLAUDICATION; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSIENT ISCHEMIC ATTACK;

ANGINA PECTORIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DEFENSINS; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; STROKE;

EID: 84864773432     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Rahman A, Isenberg DA: Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-939.
2. SANDER O, Wessel E, Richter J et al.: Disability in lupus erythematosus. Versicherungsmedizin 2006; 58: 120-125.
3. Cervera R, Khamashta MA, Font J et al.: Morbidity and mortality in systemic lupus erythematosus during a 10-year period. Medicine 2003; 82: 299-308.
4. Bruce IN: Atherogenesis and autoimmune disease: the model of lupus. Lupus 2005; 14: 687-690.
5. Hahn BH, Grossman J, Chen W, Mcmahon M: The pathogenesis of atherosclerosis in autoimmune rheumatic dseases: Roles of inflammation and dyslipidemia. J Autoimmunity 2007; 28:69-75.
6. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR: Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93: 198-200.
7. Schneider JJ, Unholzer A, Schaller M, Schäfer-Korting M, Korting HC: Human defensins. J Mol Med 2005; 83: 587-595.
8. Yang D, Liu Z-H, Tewary P, Chen Q, De La Rosa G, Oppenheim JJ: Defensin participation in innate and adaptive immunity. Curr Pharm Des 2007; 13: 3131-3139.
9. Rehaume LM, Hancock RE: Neutrophilderived defensins as modulators of innate immune function. Crit Rev Immunol 2008; 28: 185-200.
10. Seery JP: IFN-γ transgenic mice: clues to the pathogenesis of systemic lupus erythematosus? Arthritis Res 2000; 2: 437-440.
11. Tani K, Murphy WJ, Chertov O et al.: Defensins act as potent adjuvants that promote cellular and humoral immune response in mice to a lymphoma idiotype and carrier antigens. Int Immunol 2000; 12: 691-700.
12. Vordenbäumen S, Fischer-Betz R, Timm D et al.: Elevated levels of human beta-defensin 2 (hBD2) and human neutrophil peptides (HNP) in systemic lupus erythematosus. Lupus 2010; 19: 1648-1653.
13. Sthoeger ZM, Bezalel S, Chapnik N, Asher I, Froy O: High alpha-defensin levels in patients with systemic lupus erythematosus. Immunology 2009; 127: 116-122.
14. Urbonaviciene G, Frystyk J, Flyvbjerg A, Urbonavicius S, Henneberg EW, Lindholt JS: Markers of inflammation in relation to long-term cardiovascular mortality in patients with lower-extremity peripheral arterial disease. Int J Cardiol 2011 Apr 2. [Epub ahead of print]
15. Baroni A, Donnarumma G, Paoletti I et al.: Antimicrobial human beta-defensin-2 stimulates migration, proliferation and tube formation of human umbilical vein endothelial cells. Peptides 2009; 30: 267-272.
16. Grundy SM, Becker D, Clark LT et al.: Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high bolld cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106.
17. Deutsche Gesellschaft zur Bekämpfung von Fettstoffwechselstörungen und ihren Folgeerkrankungen (DGFF, Lipidliga). Empfehlungen zur Diagnostik und Therapie von Fettstoffwechselstörungen in der ärztlichen Praxis. 2009. Available at http://www.lipidliga.de.
18. Espeland MA, Craven TE, Riley WA, Corson J, Romont ABS, Furberg CD: Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thickness. Stroke 1996; 27: 480-485.
19. Hsue PY, Lo JC, Franklin A et al.: Progression of atheroskclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109: 1603-1608.
20. Furberg CD, Adams HP, Applegate WB et al.: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679-1687.
21. Taylor AJ, Villines TC, Stanek EJ et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361: 2113-2122.
22. Peng C-YJ, Lee KL, Ingersoll GM: An introduction to logistic regression analysis and reporting. J Educ Res 2002; 96: 3-14.
23. Ebrahim S, Papacosta O, Whincup P et al.: Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women. Stroke 1999; 30: 841-850.
24. Bennett L, Palucka AK, Arce E et al.: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
25. Ishii T, Onda H, Tanigawa A et al.: Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients. DNA Res 2005; 12: 429-439.
26. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C: Defensins and cathelicidins: neutrophil peptides with roles in inflammation, hyerlipidemia, and atherosclerosis. J Cell Mol Med 2005; 9: 3-10.
27. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reaktive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
28. Salonen JT, Salonen R: Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993; 87: 56-65.
29. Wendelhag I, Wiklund O, Wikstrand J: On quantifying plaque size and intima-media thickness in carotid and femoral arteries. Arterioscl Thromb Vasc Biol 1996; 16: 843-850.
30. Wickline SA: Plaque characterization: Surrogate markers or the real thing? J Am Coll Cardiol 2004; 43: 1185-1187.